KRAS and neoplasm: The alternative approach consisting in systematically repeating the whole procedure [43] (e.g. confirmation of KRAS mutations by two independent analyses) would lead to increases of the reporting delay, consuming of tumor sample, and would probably not overcome the lack of sensitivity or specificity of a single method.